This trial will study whether an experimental drug is effective and safe for people with moderate to severe asthma that isn't well controlled by current treatments.
1 Primary · 7 Secondary · Reporting Duration: at Weeks 1, 2, 4, 8, 12 and 24
3 Treatment Groups
CBP-201 Dose 1
1 of 3
CBP-201 Dose 2
1 of 3
1 of 3
306 Total Participants · 3 Treatment Groups
Primary Treatment: CBP-201 · Has Placebo Group · Phase 2
Who is running the clinical trial?
Age 18 - 75 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
How old are they?
|18 - 65||100.0%|
What site did they apply to?
|Connect Investigative Site 115||100.0%|
What portion of applicants met pre-screening criteria?
Frequently Asked Questions
Does this research currently have open enrollment?
"Affirmative. Clinicaltrials.gov confirms that this medical trial, which was first posted on May 11th 2021, is actively recruiting participants. The study requires a total of 306 patients and will be hosted in two distinct clinical facilities." - Anonymous Online Contributor
To what extent could CBP-201 put the health of participants at risk?
"Given the fact that this is a Phase 2 clinical trial, with safety data but no proof of efficacy yet, CBP-201 receives an estimated score of 2." - Anonymous Online Contributor
Does this study encompass individuals under the age of thirty?
"This medical trial is open to all people aged 18-75. There are, however, 137 clinical trials specifically for minors and 457 studies that only accept applicants over 65 years of age." - Anonymous Online Contributor
How many individuals are engaged in this clinical exploration?
"Indeed, clinicaltrials.gov has confirmed that this medical trial is actively enrolling patients. This research was initially posted on May 11th 2021 and then most recently adjusted on August 23rd 2022. The investigators are searching for 306 individuals to participate at 2 distinct locations." - Anonymous Online Contributor
Could I be considered for enrollment in this experiment?
"This medical trial is open to 306 adults aged 18-75 who are suffering from inflammation. Furthermore, participants must adhere to the following requirements: a physician's diagnosis of asthma based on GINA 2020 Guidelines; maintenance treatment with medium/high dose ICS; optional additional reliever/controller (LABA, LTRA, LAMA); potential use of third controller if necessary; daily OCS dose ≤ 10 mg prednisone or equivalent that has been consistent for 28 days prior to screening; prebronchodilator FEV1 between 40-85% at both Screening and Predose Baseline." - Anonymous Online Contributor